Dishman Carbogen Amcis Ltd Q4 FY2022 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/w1tgm417322swu98v9yt56el.pdf

Key Takeaways


India CRAMS: The Turnaround Bet

Arpit J. Vyas: "the idea is to have a less number of plants but to have a greater output and that of course will not happen in a single shot, that will happen slowly and certainly"

EDQM Remediation & Regulatory Path

Arpit J. Vyas: "we have completed almost 85% to 88% of the EDQM-related corrective actions and we are on track to extend the invitation to the European authorities as early as October or November this year."

Carbogen Amcis: Margin Mix & One-Offs

Pascal Villemagne: "They are not losing the confidence with Carbogen Amcis. Quite a contrary, they still count on us to resolve the issue and move forward"

Pipeline, Capex & Balance Sheet

Pascal Villemagne: "we have a very-very strong pipeline by the end of March, more than CHF 10 crore of the project into the pipeline, so even much more than when we ended the last year '21."

Cost Structure & Margin Recovery Path

Sanjay S. Majmudar: "I think '22-23 looks like very much a normal year that we should see both in terms of a decent normal growth and a significant improvement in profitability is expected. So, if the top line may grow say just around by 10%-odd, the bottom line or the profitability should improve much more than the top line in the current '22-23 which should signal as a return of complete normalcy."

Guidance & Commitments

CommitmentSpecificsTimeline
EDQM re-inspectionInvite European authorities for re-inspectionBest case November 2022, worst case April 2023
Carbogen Amcis AG margin recoveryReturn to 20% EBITDA margin as project mix normalizesComing quarters
Carbogen Amcis B.V. margin recoveryReturn to 32%–35% range as Vitamin D Analog sales increaseAs mix shifts
India CRAMS revenueTotal India revenue closer to ₹400 crores, CRAMS at least ₹250–260 croresFY23
India blended margin25% to 30% on ₹400 crores revenueFY23
India growth thereafter15% to 20% revenue growthYear after FY23
Group revenue growth~10% top-line growthFY23
Group EBITDA marginCloser to 24%FY23
Group long-term EBITDA margin28% to 30%Three to five years
Group long-term revenue CAGRCloser to 12% to 15%Three to five years
Annual capex run rate₹350–450 crore rangeNext few years
CWIP capitalization₹755 crores capitalizedNext 12 to 15 months
Net debt peak~US$130 million, then decline from current US$122 millionNext two to three years
French injectables revenueIncremental revenue from new facilityStart of next financial year
Contaminated batch recoveryRevenue (at least cost) booked as reversal; insurance and supplier claims filedComing quarters
Cost pass-through5% to 6% price increases to pass on incremental costsOngoing

Key Metrics

MetricQ4 FY22
Net revenue₹569 cr, record quarterly revenue
Full-year FY22 revenue₹2,140 cr, +12% YoY
Adjusted EBITDA₹84 cr, 15% of net revenue
Full-year FY22 adjusted EBITDA₹394 cr, vs ₹274 cr in FY21
Cash profit₹70 cr
Full-year FY22 cash profit₹340 cr, vs ₹254 cr in FY21
Total one-off impact₹62.34 cr, including batch impurity provision, pension provision, soil reclamation, power and fuel, IT project costs
Carbogen Amcis AG EBITDA margin14.7% for Q4; full year 18.7% vs 19.1% in FY21
Carbogen Amcis B.V. EBITDA margin29.5% for Q4; full year 30% vs 34.5% in FY21
UK entity EBITDA margin13.8% for Q4; full year 17.6% vs 19% in FY21
CRAMS India revenue₹48 cr, vs ₹23 cr in Q4 FY21
CRAMS Switzerland, France and China revenue₹375 cr, +9.4% YoY
CRAMS UK revenue₹25 cr, +16.5% YoY
Carbogen Amcis B.V. revenue₹63 cr, -13% YoY
India CRAMS operating loss₹6.5 cr
Net debtUS$122 million as of March 31, 2022
Capital work-in-progress₹755 cr
Customer advances outstanding₹250 cr as of March 31, 2022, vs ₹150 cr in FY21
Pipeline valuemore than CHF 10 crore of projects by end of March
Orders in hand yet to start~$100 million
Group-level FY23 revenue growth expectation12% to 15% CAGR over three to five years
India operations FY23 revenue expectationcloser to ₹400 cr, with blended margin of 25% to 30%
Group-level FY23 EBITDA margin targetcloser to 24%
Group-level three-to-five-year EBITDA margin expectation28% to 30%
Annual CAPEX run rate₹350–450 cr
Peak net debt expected~$130 million